Matelis Quoted in Law360 About SEC Disclosure Requirements Avenatti Extortion Case Against Nike
28 March 2019
Partner Jessica Matelis was quoted in the Law360 article, ‘Geragos ‘Chargeable’ in Avenatti Extortion Case, Experts Say.”
Matelis responded to questions of whether Nike needed to disclose in SEC filings that it was cooperating with authorities in an investigation into alleged corruption with college basketball players. Celebrity lawyers Michael Avenatti and Mark Geragos have been accused of trying to extort money from the shoemaker in connection with the alleged corruption.
Matelis told Law360 that there is no bright-line rule as to when a company needs to disclose that it is cooperating in an investigation. “It could very well be that the company was told by criminal authorities not to disclose anything,” she said.
Matelis responded to questions of whether Nike needed to disclose in SEC filings that it was cooperating with authorities in an investigation into alleged corruption with college basketball players. Celebrity lawyers Michael Avenatti and Mark Geragos have been accused of trying to extort money from the shoemaker in connection with the alleged corruption.
Matelis told Law360 that there is no bright-line rule as to when a company needs to disclose that it is cooperating in an investigation. “It could very well be that the company was told by criminal authorities not to disclose anything,” she said.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”